BioCentury
ARTICLE | Financial News

Braeburn raises $110M mezzanine round

January 12, 2018 4:35 PM UTC

Braeburn Pharmaceuticals Inc. (Princeton, N.J.) closed on Jan. 10 a $110 million mezzanine financing led by new investor Wellington Capital Management. New investors Avista Capital Partners, RA Capital Management, New Leaf Venture Partners, Deerfield Management and Rock Springs Capital also participated, as did Apple Tree Partners, Braeburn's sole investor prior to this round.

In November, a joint meeting of FDA's Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee recommended approval of some doses of Braeburn's buprenorphine injection depot (CAM2038) to treat opioid use disorder by a vote of 17-3. An NDA for CAM2038 is under Priority Review at FDA with a PDUFA date of Jan. 19 (see BioCentury, Nov. 3, 2017)...